Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management.
Liebenberg D, Gordhan BG, Kana BD.
Front Cell Infect Microbiol. 2022 Sep 23;12:943545. doi: 10.3389/fcimb.2022.943545. eCollection 2022.
Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies.
Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, Nahid P.
PLoS Med. 2018 Jul 3;15(7):e1002595. doi: 10.1371/journal.pmed.1002595. eCollection 2018 Jul.
Enhanced tuberculosis clearance through the combination treatment with recombinant adenovirus-mediated granulysin delivery.
Hao L, Ma J, Shi C, Lin X, Zhang Y, Jo-Lewis BN, Lei Q, Ullah N, Yao Z, Fan X.
Theranostics. 2020 Aug 8;10(22):10046-10056. doi: 10.7150/thno.48052. eCollection 2020.
A Mouse Model for Tuberculosis Combined With Inhalable Imiquimod-PLGA Nanocomposite Particles Based on Macrophage Phenotype.
Nii T, Takizawa S, Akita T, Yamashita C, Takeuchi I, Makino K.
In Vivo. 2022 Sep-Oct;36(5):2166-2172. doi: 10.21873/invivo.12942.
Efficacy of Dual-Targeting Combined Anti-Tuberculosis Drug Delivery System in the Treatment of Tuberculous Meningitis.
Ma W, Peng H, Liu K, Wang Y, Wang W, Qu S, Li Y, Bi L, Zhang X, Zhang L.
J Biomed Nanotechnol. 2021 Oct 1;17(10):2034-2042. doi: 10.1166/jbn.2021.3169.
Tuberculosis disease among people with HIV: therapeutic advances.
Mave V, Paradkar M, Conradie F, Gupta A, Avihingsanon A, Meintjes G, Turkova A, Dooley KE, Chaisson RE.
Lancet HIV. 2025 May;12(5):e367-e381. doi: 10.1016/S2352-3018(25)00040-2. Epub 2025 Mar 24.
Clinical management of combined tuberculosis and diabetes.
van Crevel R, Koesoemadinata R, Hill PC, Harries AD.
Int J Tuberc Lung Dis. 2018 Dec 1;22(12):1404-1410. doi: 10.5588/ijtld.18.0340.
NIR-II AIE Luminogen-Based Erythrocyte-Like Nanoparticles with Granuloma-Targeting and Self-Oxygenation Characteristics for Combined Phototherapy of Tuberculosis.
Wang H, Li B, Sun Y, Ma Q, Feng Y, Jia Y, Wang W, Su M, Liu X, Shu B, Zheng J, Sang S, Yan Y, Wu Y, Zhang Y, Gao Q, Li P, Wang J, Ma F, Li X, Yan D, Wang D, Zou X, Liao Y.
Adv Mater. 2024 Sep;36(38):e2406143. doi: 10.1002/adma.202406143. Epub 2024 Jul 28.
Anti-tuberculosis site-specific oral delivery system that enhances rifampicin bioavailability in a fixed-dose combination with isoniazid.
Luciani-Giacobbe LC, Lorenzutti AM, Litterio NJ, Ramírez-Rigo MV, Olivera ME.
Drug Deliv Transl Res. 2021 Jun;11(3):894-908. doi: 10.1007/s13346-020-00847-9. Epub 2020 Sep 8.
Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates.
Agger EM.
Adv Drug Deliv Rev. 2016 Jul 1;102:73-82. doi: 10.1016/j.addr.2015.11.012. Epub 2015 Nov 17.
